WHO ICTRP trial
Bortezomib as consolidation therapy in patients aged 60 years and younger with…
EUCTR2005-004948-31-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-004948-31-DE |
|---|---|
| Public title | Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma |
| Scientific title | Bortezomib as consolidation therapy in patients aged 60 years and younger with multiple myeloma |
| Primary sponsor | JANSSEN-CILAG GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Germany |
| Conditions | multiple myeloma in patients aged 60 years and younger having been treated before initiation of the study with a high dosage chemotherapy with melphalane followed by an autologous or allogenic stemcell transplantation MedDRA version: 14.1… |
| Interventions | Trade Name: VELCADE 3,5 mg Pulver zur Herstellung einer Injektionslösung Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Bortezomib CAS Number: 179324-69-7 Concentration unit: mg milligram(s) Concentration type… |
| Registration date | Mar 11, 2006 |
| Secondary IDs | 26866138MMY3012 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: